SCHEMBL6239419

SCHEMBL6239419

C#CCCCn1c(=O)oc(=O)c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
TSHR P16473 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
USP2 O75604 2/20 0.41
HPGD P15428 2/20 0.41
RAB9A P51151 1/20 0.41
TP53 P04637 1/20 0.40
ESR1 P03372 1/20 0.40
POLB P06746 1/20 0.40
ALOX15 P16050 1/20 0.40
PTK2B Q14289 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PGR P06401 1/20 0.39
RORA P35398 1/20 0.39
RORC P51449 1/20 0.39
RORB Q92753 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887258 0.86 ALDH1A1 (0.48) ALDH1A1NPSR1TSHRSMN1; SMN2USP2
SCHEMBL11394017 0.82 MEN1 (0.47) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL11389425 0.81 ALDH1A1 (0.51) ALDH1A1NPSR1TSHRSMN1; SMN2USP2
SCHEMBL17208786 0.81 ALDH1A1 (0.51) ALDH1A1NPSR1TSHRSMN1; SMN2USP2
SCHEMBL11688278 0.81 ALDH1A1 (0.51) ALDH1A1NPSR1TSHRSMN1; SMN2USP2
SCHEMBL1061987 0.81 PGR (0.60) ALDH1A1NPSR1HPGDPOLBPGR
SCHEMBL16864494 0.80 SLC6A4 (0.52) ALDH1A1CNR1CNR2SMN1; SMN2HPGD
SCHEMBL9786352 0.80 FABP4 (0.51) CNR1CNR2
SCHEMBL20968383 0.79 ALDH1A1 (0.54) ALDH1A1NPSR1TSHRSMN1; SMN2USP2
SCHEMBL2453991 0.79 PGR (0.55) ALDH1A1NPSR1CNR2SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 ALDH1A1 1494/4885NPSR1 3358/4885CNR1 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.